JP2018510884A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018510884A5 JP2018510884A5 JP2017552153A JP2017552153A JP2018510884A5 JP 2018510884 A5 JP2018510884 A5 JP 2018510884A5 JP 2017552153 A JP2017552153 A JP 2017552153A JP 2017552153 A JP2017552153 A JP 2017552153A JP 2018510884 A5 JP2018510884 A5 JP 2018510884A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- arylalkyl
- composition
- heteroarylalkyl
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- PRAAPINBUWJLGA-UHFFFAOYSA-N O=C(Cc1ncccc1)Nc1nnc(CCCCc2ccc(NC(Cc3cc(OC(F)(F)F)ccc3)=O)nn2)[s]1 Chemical compound O=C(Cc1ncccc1)Nc1nnc(CCCCc2ccc(NC(Cc3cc(OC(F)(F)F)ccc3)=O)nn2)[s]1 PRAAPINBUWJLGA-UHFFFAOYSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021069815A JP2021102662A (ja) | 2015-04-06 | 2021-04-16 | グルタミナーゼの阻害剤を用いる肺がんの処置 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562143494P | 2015-04-06 | 2015-04-06 | |
| US62/143,494 | 2015-04-06 | ||
| US201562149489P | 2015-04-17 | 2015-04-17 | |
| US62/149,489 | 2015-04-17 | ||
| PCT/US2016/026127 WO2016164401A1 (en) | 2015-04-06 | 2016-04-06 | Treatment of lung cancer with inhibitors of glutaminase |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021069815A Division JP2021102662A (ja) | 2015-04-06 | 2021-04-16 | グルタミナーゼの阻害剤を用いる肺がんの処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018510884A JP2018510884A (ja) | 2018-04-19 |
| JP2018510884A5 true JP2018510884A5 (enExample) | 2019-05-16 |
| JP6944377B2 JP6944377B2 (ja) | 2021-10-06 |
Family
ID=57015711
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017552153A Expired - Fee Related JP6944377B2 (ja) | 2015-04-06 | 2016-04-06 | グルタミナーゼの阻害剤を用いる肺がんの処置 |
| JP2021069815A Withdrawn JP2021102662A (ja) | 2015-04-06 | 2021-04-16 | グルタミナーゼの阻害剤を用いる肺がんの処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021069815A Withdrawn JP2021102662A (ja) | 2015-04-06 | 2021-04-16 | グルタミナーゼの阻害剤を用いる肺がんの処置 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10441587B2 (enExample) |
| EP (1) | EP3280415A4 (enExample) |
| JP (2) | JP6944377B2 (enExample) |
| KR (1) | KR20170132333A (enExample) |
| CN (1) | CN107949387B (enExample) |
| AU (1) | AU2016246521B2 (enExample) |
| BR (1) | BR112017021312A2 (enExample) |
| CA (1) | CA2981762A1 (enExample) |
| EA (1) | EA035354B1 (enExample) |
| IL (1) | IL254876A0 (enExample) |
| MX (1) | MX383034B (enExample) |
| SG (1) | SG11201708153XA (enExample) |
| WO (1) | WO2016164401A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8604016B2 (en) | 2011-11-21 | 2013-12-10 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
| HUE056078T2 (hu) | 2012-11-16 | 2022-01-28 | Calithera Biosciences Inc | Heterociklusos glutamináz inhibitorok |
| HRP20192056T1 (hr) | 2014-04-30 | 2020-02-21 | Pfizer Inc. | Derivati diheterocikla vezani na cikloalkil |
| JP6889101B2 (ja) | 2014-08-07 | 2021-06-18 | キャリセラ バイオサイエンシーズ， インコーポレイテッド | グルタミナーゼ阻害剤の結晶形態 |
| SG11201802830QA (en) | 2015-10-05 | 2018-05-30 | Calithera Biosciences Inc | Combination therapy with glutaminase inhibitors and immuno-oncology agents |
| WO2018039544A1 (en) | 2016-08-25 | 2018-03-01 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
| WO2018039441A1 (en) | 2016-08-25 | 2018-03-01 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
| AU2018231058A1 (en) * | 2017-03-10 | 2019-09-19 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
| JP7188936B2 (ja) * | 2018-08-21 | 2022-12-13 | 国立大学法人富山大学 | 抗炎症剤 |
| JP7156856B2 (ja) * | 2018-08-21 | 2022-10-19 | 国立大学法人富山大学 | 抗肥満剤 |
| WO2021076814A1 (en) * | 2019-10-15 | 2021-04-22 | Cornell University | Methods of inhibiting liver-type glutaminase, gls2 |
| US12653785B2 (en) * | 2020-05-21 | 2026-06-16 | University of Pittsburgh—of the Commonwealth System of Higher Education | Compositions and methods for administering a YAP1/WWRT1 inhibiting composition and a GLS1 inhibiting composition |
| CN111514460B (zh) * | 2020-05-22 | 2021-12-14 | 西安交通大学 | 大气压冷等离子体在抑制谷氨酰胺酶活性方面的用途及酶抑制剂 |
| CN113956233B (zh) * | 2021-10-22 | 2023-06-06 | 南方医科大学 | 一种酰胺类化合物或其药学上可接受的盐及其制备方法和应用 |
| US20250288577A1 (en) * | 2022-04-29 | 2025-09-18 | Cornell University | Methods of treating a virus infection and methods of inhibiting viral replication |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1019519A (en) | 1911-07-11 | 1912-03-05 | Oscar Martin Polin | Apparatus for making backing for teeth. |
| US6451828B1 (en) | 2000-08-10 | 2002-09-17 | Elan Pharmaceuticals, Inc. | Selective inhibition of glutaminase by bis-thiadiazoles |
| AU2002305926A1 (en) | 2001-02-05 | 2002-10-08 | Exegenics Inc. | Cysteine protease inhibitors |
| WO2005113798A2 (en) | 2004-04-15 | 2005-12-01 | University Of Florida Research Foundation, Inc. | Proteolytic markers as diagnostic biomarkers for cancer, organ injury and muscle rehabilitation/exercise overtraining |
| TWI478709B (zh) | 2008-02-19 | 2015-04-01 | Earnest Medicine Co Ltd | A useful oral or enteral composition for the recovery of bodily functions |
| US20130109643A1 (en) | 2010-05-10 | 2013-05-02 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
| US10064885B2 (en) | 2010-07-09 | 2018-09-04 | Massachusetts Institute Of Technology | Metabolic gene, enzyme, and flux targets for cancer therapy |
| WO2012068512A1 (en) | 2010-11-18 | 2012-05-24 | Deuteria Pharmaceuticals Llc | 3-deutero-pomalidomide |
| CN103030597B (zh) * | 2011-09-30 | 2014-10-01 | 南昌滨西科技有限公司 | 肾脏型谷氨酰胺酶抑制剂及其制备方法和用途 |
| CN108785305B (zh) * | 2011-11-21 | 2021-10-29 | 卡利泰拉生物科技公司 | 谷氨酰胺酶的杂环抑制剂 |
| US8604016B2 (en) | 2011-11-21 | 2013-12-10 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
| AU2013266243A1 (en) * | 2012-05-24 | 2014-12-18 | Beth Israel Deaconess Medical Center, Inc. | Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-associated cancer |
| CN104797256A (zh) | 2012-09-10 | 2015-07-22 | 细胞基因公司 | 用于治疗局部晚期乳腺癌的方法 |
| EP2895623B1 (en) | 2012-09-17 | 2018-08-22 | Agios Pharmaceuticals, Inc. | Use of e-cadherin and vimentin for selection of treatment responsive patients |
| HUE056078T2 (hu) | 2012-11-16 | 2022-01-28 | Calithera Biosciences Inc | Heterociklusos glutamináz inhibitorok |
| SG11201504022RA (en) | 2012-11-21 | 2015-06-29 | Agios Pharmaceuticals Inc | Glutamase inhibitors and method of use |
| WO2014079011A1 (en) | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
| HK1220640A1 (zh) * | 2012-12-03 | 2017-05-12 | Calithera Biosciences, Inc. | 用谷氨醯胺酶的杂环抑制剂治疗癌症 |
| WO2015061432A1 (en) | 2013-10-25 | 2015-04-30 | Calithera Biosciences, Inc. | Treatment of viral infections with inhibitors of glutaminase |
| WO2015138902A1 (en) | 2014-03-14 | 2015-09-17 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
| US10221459B2 (en) | 2014-05-13 | 2019-03-05 | Case Western Reserve University | Compositions and methods of treating cancer harboring PIKC3A mutations |
| SG11201610333VA (en) | 2014-06-13 | 2017-01-27 | Calithera Biosciences Inc | Combination therapy with glutaminase inhibitors |
| WO2016004418A1 (en) | 2014-07-03 | 2016-01-07 | Board Of Regents, University Of Texas System | Glutaminase inhibitor therapy |
| WO2016014890A1 (en) | 2014-07-24 | 2016-01-28 | Calithera Biosciences, Inc. | Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase |
| JP6889101B2 (ja) | 2014-08-07 | 2021-06-18 | キャリセラ バイオサイエンシーズ， インコーポレイテッド | グルタミナーゼ阻害剤の結晶形態 |
| WO2016054388A1 (en) | 2014-10-03 | 2016-04-07 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Glutaminase inhibitors |
| US10517844B2 (en) | 2014-11-13 | 2019-12-31 | Buck Institute For Research On Aging | Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications |
| JP6768693B2 (ja) * | 2015-03-30 | 2020-10-14 | キャリセラ バイオサイエンシーズ， インコーポレイテッド | グルタミナーゼ阻害剤を投与する方法 |
| WO2018039441A1 (en) | 2016-08-25 | 2018-03-01 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
| US20180055825A1 (en) | 2016-08-25 | 2018-03-01 | Yu Liang | Treatment of cancer with inhibitors of glutaminase |
| WO2018039544A1 (en) | 2016-08-25 | 2018-03-01 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
-
2016
- 2016-04-06 BR BR112017021312A patent/BR112017021312A2/pt not_active IP Right Cessation
- 2016-04-06 WO PCT/US2016/026127 patent/WO2016164401A1/en not_active Ceased
- 2016-04-06 KR KR1020177032006A patent/KR20170132333A/ko not_active Ceased
- 2016-04-06 SG SG11201708153XA patent/SG11201708153XA/en unknown
- 2016-04-06 EP EP16777159.1A patent/EP3280415A4/en not_active Withdrawn
- 2016-04-06 AU AU2016246521A patent/AU2016246521B2/en not_active Ceased
- 2016-04-06 MX MX2017012824A patent/MX383034B/es unknown
- 2016-04-06 EA EA201792227A patent/EA035354B1/ru not_active IP Right Cessation
- 2016-04-06 CN CN201680032522.7A patent/CN107949387B/zh not_active Expired - Fee Related
- 2016-04-06 JP JP2017552153A patent/JP6944377B2/ja not_active Expired - Fee Related
- 2016-04-06 CA CA2981762A patent/CA2981762A1/en not_active Abandoned
- 2016-04-06 US US15/091,816 patent/US10441587B2/en not_active Expired - Fee Related
-
2017
- 2017-10-03 IL IL254876A patent/IL254876A0/en unknown
-
2021
- 2021-04-16 JP JP2021069815A patent/JP2021102662A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2587013C2 (ru) | Комбинированная химиотерапия | |
| CN119317435A (zh) | 利用mta协作的prmt5抑制剂的癌症治疗 | |
| JP2016502544A5 (enExample) | ||
| CN103957917A (zh) | 用atr抑制剂治疗胰腺癌和非小细胞肺癌 | |
| JP2017513908A5 (enExample) | ||
| JP2018528185A (ja) | リポソーム型イリノテカン及びオキサリプラチンを含む組み合わせ療法を使用して転移性膵臓癌を治療するための方法 | |
| US20250319186A1 (en) | Treatment of canine cancers | |
| US20230390300A1 (en) | Neuroblastoma treatment with taurolidine hydrolysis products | |
| Vansteenkiste et al. | Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model | |
| Nobile et al. | A randomized trial of 5-fluorouracil alone versus 5-fluorouracil and high dose leucovorin in untreated advanced colorectal cancer patients | |
| EP2754441A2 (en) | Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives | |
| AU2019330954A1 (en) | Neuroblastoma treatment with taurolidine hydrolysis products | |
| US20190381058A1 (en) | Methods and compositions for treating neuroblastoma in a juvenile mammalian body | |
| Bruera et al. | Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen | |
| WO2016046316A1 (en) | Antitumor activity of multi-kinase inhibitors in colorectal cancer | |
| Weaver | Treatment of Stage III B–IV Non-Small Cell Lung Cancer | |
| WO2024233874A1 (en) | Methods for sequentially administering tas-102 and bcl-2 inhibitor for cancer treatment | |
| Zenke et al. | Phase I/II study of carboplatin plus weekly nab-paclitaxel in patients aged≥ 75 years with squamous-cell lung cancer: TORG1322 | |
| JP7530351B2 (ja) | 若年哺乳動物の身体における神経芽細胞腫を治療するための方法および組成物 | |
| Dawood | American Society of Clinical Oncology 2014: Updates in breast and gastrointestinal cancers | |
| Esmat et al. | Next Generation Sequencing (NGS) in Relapsed/Refractory HPV Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Reveals Diverse Genomic Alterations and Potential Targets of Therapy | |
| WO2025106908A1 (en) | Treatment of canine cancers | |
| WO2025030049A1 (en) | Sequential treatment method for p53-deficient cancer | |
| Krishnamurthy et al. | Treatment of small cell lung cancer | |
| WO2025193927A1 (en) | Use of mithramycin analogue for the treatment of cancer |